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Purpose: The importance of a framework for a systematic structured assessment of
the benefits and risks has been established, but in addition, it is necessary that the
benefit-risk decisions and the processes to derive those decisions are documented
and communicated to various stakeholders for accountability. Hence there is now a
need to find appropriate tools to enhance communication between regulators and other
stakeholders, in a manner that would uphold transparency, consistency and standards.
Methods: A retrospective, non-comparative study was conducted to determine
the applicability and practicality of a summary template in documenting benefit-risk
assessment and communicating benefit-risk balance and conclusions for reviewers to
other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was
evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences
Authority (HSA).
Results: The BR Summary Template was found to be adequate in documenting
benefits, risks, relevant summaries and conclusions, while the User Manual was useful
in guiding the reviewer in completing the template. The BR Summary Template was
also considered a useful tool for communicating benefit-risk decisions to a variety of
stakeholders.
Conclusions: The use of a template may be of value for the communicating benefit-risk
assessment of medicines to stakeholders.
Keywords: benefit–risk assessment, benefit–risk methodologies, pharmaceutical industry, regulatory
agency, framework, documentation
Background
Regulators are challenged to review the overall balance between the benefits and the associated risks
of new drugs rather than the impact of individual components (Breckenridge, 2010). In this context,
the key components for effective regulation are transparency and accountability underpinned by
the use of a structured framework that aids in the communication of the differences in opinion
between regulators and the drug developers (World Health Organization, 2003). Commenting on
innovations in regulatory science, Leufkens and Eichler suggested that there are three dimensions in
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this area. First, regulators should keep current their
understanding of the science and technologies that help in
drug development and the advancement in innovation. Second,
new standards and tools should be developed to evaluate and
assess the benefit-risk balance of medicines to facilitate a sound
and transparent decision-making process. Last, the entire system
should be monitored for its impact on patient safety, public
health and meeting medical needs (Leufkens and Eichler, 2011).
Therefore, it is likely that a new overarching framework would
be required to encompass these new initiatives.
In the European Medicines Agency’s (EMA) Roadmap to
2015, one of the strategic areas identified was facilitating the
access of medicines through reinforcing the benefit-risk balance
assessment model, to be achieved through a set of priority
activities. These included looking at appropriate quantitative
tools, improving the quality and consistency of the outcomes,
reviewing the European Public Assessment Reports (EPARs) to
improve communication of benefit-risk decisions to stakeholders
and increasing the involvement of patients, academia and
healthcare professionals in the assessment of medicines to ensure
their views are taken into consideration (European Medicines
Agency, 2011).
EMA proposed PROACT-URL (Problem formulation,
Objectives, Alternatives Consequences, Tradeoffs, Uncertainties,
Risk tolerance, Linked decisions), a benefit-risk framework that
consists of eight steps (European Medicines Agency, 2010), and
beginning in 2009, the US Food and Drug Administration (FDA)
have taken initiatives to explore systematic approaches to assess
and communicate benefits and risks (Centre for Innovation in
Regulatory Science, 2011; US Food and Drug Administration,
PDUFA, 2012; US Food and Drug Administration, 2013).
In addition, over the next few years, the Therapeutic Goods
Administration (TGA) of Australia will be focusing on
increasing transparency and engaging stakeholders with a new
framework for communication that includes the benefits vs. risks
approach in their regulation of medicine (Therapeutic Goods
Administration, 2013).
At the same time, the pharmaceutical industry has been taking
the initiative to address the need for an improved benefit-risk
assessment of medicines by developing a structured, systematic,
and transparent framework. The Pharmaceutical Research and
Manufacturers of America (PhRMA), the Benefit-Risk Action
Team (BRAT) Framework sought to incorporate all the relevant
aspects of benefits and risks in drug development in both
qualitative and quantitative analyses (Coplan et al., 2011; Levitan,
2012).
Leong and colleagues explored need for a universal benefit-
risk framework for medicines within regulatory agencies and
pharmaceutical companies and the status of its development
(Leong et al., 2013). The advantages of a universal framework
reported by both these groups were similar to those mentioned
earlier, while the main hurdle to its establishment was the lack
of an accepted, validated, and international model. Although
stakeholders are looking forward to a change, the benefit-risk
system that is likely to be adopted is an overarching, semi-
quantitative framework that incorporates a toolbox of various
benefit-risk methodologies. As a response to this ongoing need,
a workshop was organized that brought together regulators and
the pharmaceutical industry, where the attendees agreed the
common elements of an overarching, internationally acceptable,
standardized benefit-risk framework (Figure 1), known as the
Universal Methodologies for Benefit-Risk Assessment (UMBRA)
(Centre for Innovation in Regulatory Science, 2012).
In collaboration with the Centre for Innovation in Regulatory
Science (CIRS), TGA, the Singapore’s Health Sciences Authority
(HSA), Health Canada and Swissmedic, a Consortium on
Benefit-Risk Assessment (COBRA), was formed that aimed to
develop a systematic qualitative approach for the benefit-risk
assessment of medicines in order to facilitate joint or shared
reviews by these four agencies. A benefit-risk documentation
template (BR Template), was developed based on the EMA
reflection paper on benefit-risk assessment (European Medicines
Agency, 2008) and reviewed by the Consortium through both
retrospective and prospective studies employing its use, with
plans for making the template more reflective of actual practice
(Centre for Innovation in Regulatory Science, 2012).
Notwithstanding recent initiatives by both EMA (European
Medicines Agency, 2008, 2010) and US FDA, there is currently
no standard template for the documentation and communication
of the evaluation outcomes of benefit-risk decisions. Hence there
is a need to find appropriate tools to enhance communication
in a manner that would uphold transparency, consistency and
appropriate standards. It was proposed therefore, that a summary
version of the full BR Template that had been developed
and evaluated by COBRA, which could collate the relevant
conclusions leading to the final benefit-risk decision, might
also be useful in documenting and communicating benefit-risk
decisions for the emerging markets. Hence this study aimed
to determine the value of the use of a summary template in
documenting the benefit-risk assessment of medicines during the
review and communicating benefit-risk balance and conclusions,
among regulators in the emerging markets and also to other
stakeholders including the industry and health technology
assessment agencies. In addition, the effectiveness of a user
manual in guiding a reviewer to complete the summary template
was also evaluated.
Materials and Methods
This research was conducted as a retrospective, non-comparative
study at the HSA Singapore, an established regulatory agency
from the emerging markets. The BR Template used by
the Consortium was reviewed and its Benefit-Risk Summary
section was extracted to produce the BR Summary Template
(Supplementary Material). A User Manual was also created
as was the study evaluation tool to review the uses of both
BR Summary Template and User Manual. The overall study
package including the study protocol, BR Summary Template,
User Manual (Supplementary Material) and the study evaluation
tool (Supplementary Material) was sent to 16 clinical reviewers
in HSA involved in assessing the benefit-risk balance and
registration of medicines. The reviewers were asked to identify
an appropriate product application based on the following
criteria:
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FIGURE 1 | The UMBRA framework. Reprinted with permission, Centre for Innovation in Regulatory Science.
• A new drug application that requires a benefit-risk evaluation;
• An abridged review, applicable to products having obtained a
marketing approval in at least one country;
• A regulatory decision (having received marketing approval or
a confirmed benefit-risk decision) obtained within the last 3
months.
The reviewers transferred the relevant information required for
the BR Summary Template from their respective completed
clinical assessment reports (as per current processes in HSA)
with the support of the User Manual. Following this transfer, the
reviewers completed the study evaluation tool. The evaluation
was to assess the entire experience of using the BR Summary
Template. All responses were collated into a single group
and the outcomes are presented according to their respective
sections in the study evaluation tool. All data were expressed
as percentage over number of respondents for that item. Free-
text comments were collated and presented in appropriate
categories where necessary. This was designed as an exploratory
and descriptive study and the outcomes were interpreted to
provide qualitative inferences relating to the aims. This was an
exploratory qualitative study and therefore no statistical analyses
were planned or conducted. The results were displayed using
descriptive statistics.
Results
A total of 12 responses were received by August 2013. Of the four
who did not respond, one was transferred to another unit, two
did not have applications that met the criteria and the remaining
one did not respond. Nine of the respondents had between 1 and
5 years of working experience in the agency, with one having less
than 1 year and two having more than 5 years. As the reports
were written independently, the responses actually represented
the evaluation of 10 different products reviewed via the abridged
route.
Part I—User-friendliness of the BR Summary
Template and the User Manual
The template has two functions to help users navigate the
document, namely the “Go to page” button and page thumbnails
to locate a specific page. These are aimed at reducing the effort
required to move between different sections. The “Go to page”
button appeared to be the more useful, as 10 reviewers rated
it either good or excellent. Seven respondents indicated that
the page thumbnails were fair or were not used and it was
commented that the thumbnail icons were too small to decipher
the contents and bookmarks might have been more effective,
although none rated the BR Summary Template as not user-
friendly. There was a suggestion to include a “Back” button to
the content page or another primary page.
The User Manual was provided to guide the reviewer on the
steps to complete the template, as well as to clarify the common
terms used in the template. Between 9 and 12 respondents
rated the clarity, comprehensiveness and applicability of the User
Manual as “good.”
None rated themanual as poor for any of the three parameters.
Comments received included the suggestion to provide examples
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or a case study in the manual to better illustrate the use
of the template. It was also concluded that an inexperienced
reviewer might find the manual insufficiently comprehensive.
Even though the User Manual provided instructions with regard
to assigning relative importance to benefit and risk parameters,
the lack of experience by the reviewers may have prevented them
from effectively completing the BR Summary Template in this
aspect.
Part II—Appropriateness (Fit for Purpose) of the
Documentation of the BR Summary Template
The appropriateness of a template is dependent on its
capability to present the processes leading to the final benefit-
risk conclusion in a structured and systematic manner.
In documenting the various conclusions, the BR Summary
Template was largely thought to be fit for purpose by 11–12
respondents (Figure 2).
One modification suggested was to clarify the difference
between the clinical conclusion section and the overall
conclusion for benefit-risk balance, as it might appear redundant
if misunderstood. The other modification recommended was
to make more guidance on writing the non-clinical conclusion
available, as some reviewers were not familiar with providing
details for this section.
The template’s ability to document the benefits and risks
of the product being evaluated was affirmed by 11–12 of the
respondents (Figure 3). One respondent was unsure of the
usefulness of the template in documenting relevant benefits and
risks as identified by the sponsor and rated these parameters as
not fit for purpose, as the reviewer would eventually indicate
the benefits and risks that are to be included for assessment.
However, the purpose of listing benefits identified by the sponsor
and the reasons for inclusion or exclusion by the reviewer in the
template is the transparent and full provision of the rationale for
the benefit-risk decision. Another respondent felt that there must
be greater clarity in the template in defining risks considered
critical to the benefit-risk assessment, and as a result this reviewer
rated the documentation of inclusion or exclusion of all risks as
being not fit for purpose.
The exercise of indicating relative importance and numerical
values in the identified benefits and risks is aimed at improving
the articulation of the basis of the benefit-risk decision. While
the majority of the respondents believed it was fit for purpose,
3–4 felt that the template required modifications or was not fit
for purpose (Figure 4). The reasons and comments are listed
in Table 1 and can be seen as proposed amendments to the
template to improve documentation of weights and values. It can
be concluded that the lack of understanding of weighting and
valuing in general is the root cause of the above observation.
Overall, the BR Summary Template appeared to be able to
document study outcomes and relevant benefit-risk information
leading to a regulatory recommendation, with 10–11 of
respondents agreeing on this (Figure 5).
With regards to documenting study outcomes, one
respondent recommended modification to allow for applications
based on bibliographic submission or published literature.
Another respondent who rated the template “not fit” for
presenting study outcomes commented that this section did
not contribute to the overall benefit-risk assessment. As for
the template being useful in presenting information leading to
a regulatory recommendation, one respondent indicated that
more clarification on weighting should be provided in order to
achieve this purpose.
As for presenting an overall summary of the adverse events
or effects, half of the respondents felt that either a modification
was required, or the template was “not fit” for this purpose.
The amendments required are listed in Table 2 and are largely
technical in nature to accommodate other formats for uploading
safety information.
Part III—Applicability of the BR Summary
Template
The primary goal of the BR Summary Template is to
communicate regulatory decision making to internal or external
FIGURE 2 | Documentation of relevant information supporting the benefit-risk decision.
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FIGURE 3 | Documentation of benefits and risks.
FIGURE 4 | Documentation of weights and values.
TABLE 1 | Amendments required to improve the documentation of weights and values.
Modifications required
Clarification on how to assign weights
Provide more instructions on how to complete these sections on weighting and valuing
Recommend a consistent approach for weighting through a drop-down list of either numerical ranking or qualitative descriptors
Recommend a free text box for cases whereby the weightings are not clear-cut
Clarify if the weightings are to add up to 100% for both the benefits and risks, or are they to be considered separately for each component
Provide some examples to illustrate the intention of the sections
Reasons not being fit for purpose
Not sure how to complete these sections
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FIGURE 5 | Documentation of study outcomes, safety information and overall conclusion.
TABLE 2 | Amendments required to improve the documentation of overall summary of adverse events and effects.
Modifications required Reasons being not fit for purpose
Allow text format, PDF snapshots or other common formats besides the picture formats This section does not serve the overall benefit-risk
assessment
Further categorization to listing of common treatment-emergent AEs, serious AEs, death, discontinuations, etc. Difficulties in attaching the PDF file
As the studies had different safety endpoints, there was
no pooled summary
stakeholders. All the respondents found the template effective
in promoting communication to stakeholders (Figure 6), and
10 of respondents believed it could help achieve consistency
of decisions between regulatory agencies. However, one
respondent commented that with the different weightings
applied, consistency in regulatory decisions across agencies
cannot be achieved.
Four respondents felt that the template did not confer
any additional advantage over the current processes in the
organization. For new users, this approach generally appears
more difficult to use than the current HSA report template as the
system in use is more efficient and reaches the same conclusion.
Incidentally, the BR Summary Template is a repeat of a section
of the existing HSA current report template. Moreover, the BR
Summary Template was formatted as a PDF, which makes the
use and uploading of information more tedious compared with
the existing Word document.
When asked, 11 of respondents were willing to share the
completed BR Summary Template with healthcare professionals
and other regulatory agencies (Figure 7). One respondent
indicated sharing with health technology assessment (HTA)
agencies was not applicable since HTA agencies are not currently
in use in Singapore. One respondent commented that the
template could not adequately describe the benefit-risk findings.
Reservations in sharing with patients, patient advocacy groups,
media and in public domains included the use of technical
terms and medical jargon being unsuitable for lay persons, which
may lead to confusion and misinterpretation. This challenge
in understanding could invite unnecessary criticism and one
respondent suggested that only selected sections be made
available to such stakeholders.
Part IV—General Amendments to the BR
Summary Template
One reviewer suggested combining the identification of
benefits and risks with the exercise of assigning weights and
values to avoid repetition. However, this suggestion could be
accommodated by auto-populating the benefits and risks in
Section Results of the template into Section 6 (Supplementary
Material). It was commented that more guidance could be given
on listing the reasons for inclusion or exclusion of benefits,
such as local disease burden, available alternatives, strength
of evidence, clinical relevance and convenience to patients.
For completeness, one reviewer recommended adding another
section to indicate if the benefit-risk balance is positive or
negative, before being asked to provide reasons for a negative
benefit-risk balance. While this study was conducted for new
active substances, one reviewer recommended that the template
could be amended to accommodate clinical variations.
Discussion
The findings of this study showed that the successful
implementation of a new process or tool in an established
regulatory agency is dependent on the fundamental
understanding of the principles behind their use. Weighting
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FIGURE 6 | Applicability of BR Summary Template.
FIGURE 7 | Willingness to share the BR Summary Template with various stakeholders.
and valuing is seen as an explicit presentation of the subjective
interpretation of clinical information. This exercise aimed to
enhance the transparency of decision making by making it
clear that the priorities placed on a set of benefits and risks
ultimately affect the resulting benefit-risk balance. However,
the concept of weighting or assigning relative importance and
valuing is a technique that is relatively new to both HSA and
possibly other regulatory agencies (Leong et al., 2013). Without
an understanding of the rationale behind weighting and valuing,
some reviewers could not appreciate its contribution to effective
documentation and communication.
For improved use, the current BR Summary Template
would require a revision to the technical capabilities and an
improvement for the documentation of safety information and
adverse events. In addition, the User Manual should be revised
to include examples and case studies to better illustrate the
use of the template. However, it appears that the capacity
of the BR Summary Template to effectively communicate a
benefit-risk decision has been clearly exhibited, as supported
by the reviewers who were willing to share this template with
stakeholders.
It is also appropriate to examine the utility of this template
as a means of transferring knowledge and communicating the
basis of a decision and the reviewers in this study indicated
their willingness to share the completed BR Summary Template
for a specific product with other regulatory agencies where
there is a memorandum of understanding. For major regulatory
agencies it may be a requirement to provide details of the
evaluation to achieve a level of transparency stipulated by the
jurisdiction. However, this study has demonstrated that the BR
Summary Template, even in the absence of these details, is an
effective tool to communicate benefit-risk decisions. Therefore,
it may be considered as a basic report template for agencies
that are in transition to build up their evaluation capabilities
and would be an ideal tool for communicating benefit-risk
decisions to regulatory agencies in jurisdictions with emerging
pharmaceutical markets, since the components of the template
address the basic needs of a sound and scientific discussion.
Indeed, for regulatory agencies in emerging markets that are
more resource constrained with respect to their scientific
capabilities, the BR Summary Template may serve as a template
for the assessment of medicines and as an internal standard
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in their pursuit to develop the capabilities of their agencies.
There should be further studies to assess the use of the BR
Summary Template in aiding emerging markets in their pursuit
of improving their regulatory standards. This is in line with the
earlier findings from a CIRS workshop to include the emerging
markets earlier in the development of benefit-risk frameworks, so
as to increase the worldwide acceptance of a universal framework
(Centre for Innovation in Regulatory Science, 2008). It is only
through a global understanding of the need for a common
template that consistency in evaluating benefits and risks can
be achieved. In addition, a fuller understanding of the utility of
the tool could be obtained through further studies to examine
the value of the tool in communicating benefit-risk decisions to
healthcare professionals, patients and other stakeholders.
The limitations of this study were namely small sample size,
single emerging market and the non-responders. However, the
value of the study largely lies with the establishment of the
applicability and practicality of such methodology which was
introduced to the region for the first time. Nevertheless, the
findings of the study and the use the BR Summary Template and
the User Manual by the HSA reviewers proved to be useful, but
would benefit from further validation studies.
The outcome of this study, involving reviewers within HSA
Singapore as representative of the emerging markets in the
region, has demonstrated that the principles of the BR Summary
Template may be applicable to other jurisdictions or similar
agencies, further evidence, however, from other countries in the
region implementing the BR Summary Template should support
this claim. This is indeed encouraging in the current climate,
where the debate surrounding the benefit-risk assessment of
medicines is on the top of many regulatory agencies’ agenda.
Thus, the promising features of the BR Summary Template will,
no doubt, contribute to such on-going discussion.
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